Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Breast Cancer
Interventions: p16INK4a mRNA level assessment, organ-specific protein signatures assessment; Diagnostic Test
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 22 Years to 66 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Prematurity
Interventions: Protein Hydrolyzed Premature Formula; Other
Lead sponsor: University of Miami; Other
Eligibility: 3 Days to 6 Months
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Severe Obesity, Obesity, BMI Greater Than 30
Interventions: Tirzepatide, Standard of Care post-gastric bypass; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 25 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Type 1 Diabetes Mellitus
Interventions: TAK-329, Insulin, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Acetaminophen Overdose
Interventions: Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free), Acetadote; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 14
States / cities: Phoenix, Arizona • Loma Linda, California • Orange, California + 11 more

Conditions: Cicatrix
Interventions: Juvista (avotermin); Drug
Lead sponsor: Renovo; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy
Interventions: Pregabalin controlled release, 330 mg, 600- 750 calorie, Pregabalin controlled release, 330 mg, fasted, Pregabalin immediate release, 300 mg; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
Interventions: SBP-101, Nab-paclitaxel, Gemcitabine, Placebo; Drug · Other
Lead sponsor: Panbela Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 14
States / cities: Hot Springs, Arkansas • Fullerton, California • New Haven, Connecticut + 11 more

Conditions: Ocular Inflammation
Interventions: rEV131, Prenisolone sodium phosphate 1.0%, rEV131 vehicle; Drug
Lead sponsor: Evolutec Group; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: North Andover, Massachusetts

Conditions: Pain
Interventions: Lumbar sympathetic block with Botulinum Toxin type A; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Stanford, California

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2605541, Human Insulin NPH, Oral Antihyperglycemic Medications (OAM); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 641 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 20
States / cities: Tempe, Arizona • Concord, California • Fresno, California + 17 more

Conditions: HIV Infections
Interventions: MTP-PE/MF59, Env 2-3; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Prediabetes, Obesity
Interventions: Foods rich in high quality protein; Dietary Supplement
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 55 Years and older · Male only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: Exenatide once weekly suspension, Exenatide twice daily; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 58
States / cities: Muscle Shoals, Alabama • Mesa, Arizona • Phoenix, Arizona + 52 more

Conditions: Multiple Sclerosis Relapse
Interventions: Teriflunomide, Placebo (for teriflunomide), Interferon-beta (IFN-beta); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 32
States / cities: Cullman, Alabama • Cordova, Alaska • Phoenix, Arizona + 26 more

Conditions: Kidney Cancer
Interventions: Interleukin-2; Drug
Lead sponsor: Loyola University; Other
Eligibility: 16 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 15
States / cities: Duarte, California • Los Angeles, California • Oakland, California + 11 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin Degludec, Insulin Glargine; Drug
Lead sponsor: Yale University; Other
Eligibility: 8 Years to 18 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Rheumatoid Arthritis (RA), Crohn's Disease (CD), Ulcerative Colitis (UC)
Interventions: Ketogenic diet, Carnivore (Lion) Diet; Behavioral
Lead sponsor: Fuller Research Foundation; Other
Eligibility: 18 Years to 64 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Colorectal Cancer, Peritoneal Metastases, Carcinomatosis
Interventions: Cyclophosphamide, Fludarabine, Cetuximab, NK Cells; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Post-polio Syndrome
Interventions: Flebogamma® 5% DIF, Placebo; Biological · Drug
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 4
States / cities: St Louis, Missouri • Syracuse, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride, zosuquidar trihydrochloride, Placebo; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 60 Years and older
Enrollment: 449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 91
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 67 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Cagrilintide, Semaglutide, Tirzepatide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,023 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 54
States / cities: Pelham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more

Conditions: Panic Disorder
Interventions: Cognitive behavioral therapy, D-cycloserine; Behavioral · Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Hartford, Connecticut • Boston, Massachusetts

Conditions: Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour
Interventions: Octreotide LAR, 177Lu-DOTA0-Tyr3-Octreotate; Drug
Lead sponsor: Advanced Accelerator Applications; Industry
Eligibility: 18 Years and older
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 13
States / cities: Los Angeles, California • Palo Alto, California • Tampa, Florida + 9 more

Search by objective public record fields.

A Novel Approach Utilizing Organ Specific Age Proteomics

Hydrolized Protein Formula for Premature Infants

GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

TAK-329 Glucose Clamp Study

Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection

Juvista in Scar Revision Surgery of Disfiguring Scars

Investigation Of Absorption And Pharmacokinetics Of A Single Dose Of Controlled Release Pregabalin Tablet Administered Fasted In The Evening or Immediately Following A 600-750 Calorie Evening Meal As Compared To Single Dose Of Immediate Release Pregabalin Capsule In Healthy Volunteers

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery

A Pilot Clinical Trial of Sympathetic Blockade With Botulinum Toxin Type A to Treat Complex Regional Pain Syndrome (CRPS): a Randomized, Double-Blind, Controlled, Crossover Trial.

A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes

A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)

Veterans Achieving Weight Loss and Optimizing Resilience-Using Protein

Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer

Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin

Ketogenic and Carnivore (Lion) Diets for Inflammatory Bowel Disease and Rheumatoid Arthritis

Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome

Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

Augmenting Exposure Therapy With an N-Methyl-D-Aspartate (NMDA) Agonist for Panic Disorder

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours